Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice

References

• Sparks JA, Barbhaiya M, Karlson EW, et al. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: rationale and design of the cardiovascular inflammation reduction Trial-Adverse events (CIRT-AE) study. Semin Arthritis Rheum. 2017;47(1):1–9.
   PubMed Web of Science ®Google Scholar
• Warren RB, Weatherhead SC, Smith CH, et al. British association of dermatologists” guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175(1):23–44.
   PubMed Web of Science ®Google Scholar
• Swedish Society for Dermatology and Venereology (SSDV). Treatment recommendations for systemic treatment of psoriasis. Accessed Jan 2023. https://ssdv.se/images/SSDVs_behandlingsrekommendationer_for_systemisk_behandli_ng_av_psoriasis_2023-03-16.pdf.
   Google Scholar
• No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460–466.
   PubMed Web of Science ®Google Scholar
• Swedish Society for Dermatology and Venereology (SSDV). treatment recommendations for systemic treatment of psoriasis. Accessed Jan 2023. https://ssdv.se/images/SSDVs_behandlingsrekommendationer_for_systemisk_behandli_ng_av_psoriasis.pdf.
   Google Scholar
• West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLOS One. 2016;11(5):e0153740.
   PubMedGoogle Scholar
• Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286.
   PubMed Web of Science ®Google Scholar
• Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis. Br J Dermatol. 2021;184(3):415–424.
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020;6(1):e001117.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Exton LS, Jabbar-Lopez Z, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol. 2016;136(8):1584–1591.
   PubMed Web of Science ®Google Scholar
• Daudén E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish registry of adverse events for biological therapy in dermatological diseases (BIOBADADERM) registry. J Am Acad Dermatol. 2020;83(1):139–150.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol. 2018;138(4):760–767.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Kim SC, Lee MP, et al. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol. 2019;155(10):1142–1152.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Elinder CG. The Stockholm CREAtinine measurements (SCREAM) project: fostering improvements in chronic kidney disease care. J Intern Med. 2022;291(3):254–268.
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare. National guidelines for psoriasis care: Support for governance and management. 2019. date access: Jan 2023. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2019-3-11.pdf.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European medicines agency. Am J Kidney Dis. 2020;75(1):84–104.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Fu EL, Vestergaard SV, et al. Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations. Kidney Int. 2023;103(1):53–69.
   PubMed Web of Science ®Google Scholar
• Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14–20.
   PubMed Web of Science ®Google Scholar
• Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585–612.
   PubMed Web of Science ®Google Scholar
• Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol. 1989;28(2):147–153.
   PubMedGoogle Scholar
• Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20(4):639–644.
   PubMed Web of Science ®Google Scholar
• Ohosone Y, Okano Y, Kameda H[, et al. Toxicity of low-dose methotrexate in rheumatoid arthritis–clinical characteristics in patients with MTX-induced pancytopenia and interstitial pneumonitis. Ryumachi. 1997;37(1):16–23.
   PubMedGoogle Scholar
• Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572–581.
   PubMed Web of Science ®Google Scholar
• Xu S, Gao X, Deng J, et al. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges. 2021;19(1):47–56.
   Web of Science ®Google Scholar
• Falsetti L, Sampaolesi M, Riccomi F, et al. Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy. BMJ Case Rep. 2020;13(3):e233526.
   PubMedGoogle Scholar
• Cepeda J, Liedke C, Patnaik A, et al. Development of thrombotic thrombocytopenic purpura in association with the monoclonal antibody, golimumab, used to treat rheumatoid arthritis, in a case with literature review. JCR: j Clin Rheumatol. 2018;24(4):229–231.
   PubMed Web of Science ®Google Scholar
• Baysal M, Ümit EG, Saritaş F, et al. Drug induced thrombotic microangiopathy with certolizumab pegol. Balkan Med J. 2018;35(5):398–399.
   PubMed Web of Science ®Google Scholar
• Harada Y, Yamamoto H, Sato M, et al. Autoimmune hemolytic anemia during adalimumab treatment for plaque psoriasis. Intern Med. 2015;54(9):1103–1104.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate. Ann Intern Med. 2020;172(6):369–380.
   PubMed Web of Science ®Google Scholar
• Munera-Campos M, Vilar-Alejo J, Rivera R, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. J Dermatolog Treat. 2022;33(4):2110–2117.
   PubMed Web of Science ®Google Scholar
• Shetty A, Cho W, Alazawi W, et al. Methotrexate hepatotoxicity and the impact of nonalcoholic fatty liver disease. Am J Med Sci. 2017;354(2):172–181.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol. 2021;84(6):1636–1643.
   PubMed Web of Science ®Google Scholar
• Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–564.e3.
   PubMed Web of Science ®Google Scholar
• Lopetuso LR, Mocci G, Marzo M, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver. IJMS. 2018;19(8):2199.
   Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30–e41.
   PubMed Web of Science ®Google Scholar
• Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, et al. Liver injury in psoriasis patients receiving Ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting. Actas Dermo-Sifiliográficas (English Edition). 2015;106(6):470–476.
   Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2000;30(3):196–208.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol. 1995;22(1):38–40.
   PubMed Web of Science ®Google Scholar
• Seideman P, Müller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol. 1993;20(7):1126–1128.
   PubMed Web of Science ®Google Scholar
• Sparks JA, Vanni KMM, Sparks MA, et al. Effect of low-dose methotrexate on eGFR and kidney adverse events: a randomized clinical trial. J Am Soc Nephrol. 2021;32(12):3197–3207.
   PubMed Web of Science ®Google Scholar
• Lee JS, Oh JS, Kim Y-G, et al. Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int. 2020;40(5):765–770.
   PubMed Web of Science ®Google Scholar
• Sumida K, Molnar MZ, Potukuchi PK, et al. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93(5):1207–1216.
   PubMed Web of Science ®Google Scholar
• Zee J, Mansfield S, Mariani LH, et al. Using all longitudinal data to define time to specified percentages of estimated GFR decline: a simulation study. Am J Kidney Dis. 2019;73(1):82–89.
   PubMed Web of Science ®Google Scholar
• Dobry AS, Quesenberry CP, Ray GT, et al. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77(5):838–844.
   PubMed Web of Science ®Google Scholar
• Dávila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137(2):313–321.
   PubMed Web of Science ®Google Scholar
• Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: prospective meta-analysis of psonet registries. J Am Acad Dermatol. 2017;76(2):299–308.e16.
   PubMed Web of Science ®Google Scholar
• Wang Y-C, Lin Y-H, Ma S-H, et al. Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2022;36(12):2301–2315.
   PubMed Web of Science ®Google Scholar
• Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160(3):622–628.
   PubMed Web of Science ®Google Scholar